Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

The Lancet Oncology

Volumn 17, Issue 7, 2016, Pages 917-927

  Choueiri, Toni K ^a   Escudier, Bernard ^b   Powles, Thomas ^c   Tannir, Nizar M ^d   Mainwaring, Paul N ^e   Rini, Brian I ^f   Hammers, Hans J ^g   Donskov, Frede ^h   Roth, Bruce J ⁱ   Peltola, Katriina ^j   Lee, Jae Lyun ^k   Heng, Daniel Y C ^l   Schmidinger, Manuela ^m   Agarwal, Neeraj ⁿ   Sternberg, Cora N ^o   McDermott, David F ^p   Aftab, Dana T ^q   Hessel, Colin ^q   Scheffold, Christian ^q   Schwab, Gisela ^q   Hutson, Thomas E ^r   Pal, Sumanta ^s   Motzer, Robert J ^t   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d UNIVERSITY OF TEXAS   (United States)

^e Icon Cancer Centre Wesley   (Australia)

^f LERNER RESEARCH INSTITUTE   (United States)

^g JOHNS HOPKINS UNIVERSITY   (United States)

^h AARHUS UNIVERSITY HOSPITAL   (Denmark)

ⁱ WASHINGTON UNIVERSITY   (United States)

^j HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^k University of Ulsan College of Medicine   (South Korea)

^l UNIVERSITY OF CALGARY   (Canada)

^m MEDICAL UNIVERSITY OF VIENNA   (Austria)

ⁿ UNIVERSITY OF UTAH   (United States)

^o SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^p BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^q EXELIXIS INC   (United States)

^r BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^s CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^t MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CABOZANTINIB; EVEROLIMUS; ANILIDE; ANTINEOPLASTIC AGENT; PYRIDINE DERIVATIVE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; ANEMIA; ARTICLE; ASPERGILLOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG FATALITY; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOMAGNESEMIA; INTENTION TO TREAT ANALYSIS; KARNOFSKY PERFORMANCE STATUS; KIDNEY CARCINOMA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; OVERALL SURVIVAL; PATIENT MONITORING; PHASE 3 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; AGED; CANCER STAGING; CARCINOMA, RENAL CELL; CLINICAL TRIAL; FOLLOW UP; KIDNEY NEOPLASMS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS; SECONDARY; SURVIVAL RATE;

AGED; ANILIDES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; EVEROLIMUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PYRIDINES; SURVIVAL RATE;

EID: 84991063392     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(16)30107-3     Document Type: Article

References (30)

1. 1 Motzer, RJ, Jonasch, E, Agarwal, N, et al. Kidney cancer, version 3. 2015. J Natl Compr Canc Netw 13 (2015), 151–159.
2. 2 Powles, T, Staehler, M, Ljungberg, B, et al. Updated EAU guidelines for clear cell renal cancer patients who fail VEGF targeted therapy. Eur Urol 69 (2016), 4–6.
3. 3 Motzer, RJ, Escudier, B, McDermott, DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373 (2015), 1803–1813.
4. 4 Yakes, FM, Chen, J, Tan, J, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 10 (2011), 2298–2308.
5. 5 Gibney, GT, Aziz, SA, Camp, RL, et al. c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. Ann Oncol 24 (2013), 343–349.
6. 6 Gustafsson, A, Martuszewska, D, Johansson, M, et al. Differential expression of Axl and Gas6 in renal cell carcinoma reflecting tumor advancement and survival. Clin Cancer Res 15 (2009), 4742–4749.
7. 7 Rankin, EB, Fuh, KC, Castellini, L, et al. Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET. Proc Natl Acad Sci U S A 111 (2014), 13373–13378.
8. 8 Zhou, L, Liu, XD, Sun, M, et al. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene, 2015 Sept 14, 10.1038/onc.2015.343.
9. 9 Harshman, LC, Choueiri, TK, Targeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinoma. Cancer J 19 (2013), 316–323.
10. 10 Pinato, DJ, Chowdhury, S, Stebbing, J, TAMing resistance to multi-targeted kinase inhibitors through Axl and Met inhibition. Oncogene, 2015 Oct 5, 10.1038/onc.2015.374.
11. 11 Choueiri, TK, Escudier, B, Powles, T, et al. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med 373 (2015), 1814–1823.
12. 12 Eisenhauer, EA, Therasse, P, Bogaerts, J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45 (2009), 228–247.
13. 13 Motzer, RJ, Bacik, J, Schwartz, LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22 (2004), 454–463.
14. 14 Ljungberg, B, Bensalah, K, Canfield, S, et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 67 (2015), 913–924.
15. 15 National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) version 4. http://evs.nci.nih.gov/ftp1/CTCAE/About.html (accessed Jan 28, 2015).
16. 16 Spigel, DR, Ervin, TJ, Ramlau, RA, et al. Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 31 (2013), 4105–4114.
17. 17 Santoro, A, Rimassa, L, Borbath, I, et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol 14 (2013), 55–63.
18. 18 Ko, JJ, Xie, W, Kroeger, N, et al. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Lancet Oncol 16 (2015), 293–300.
19. 19 Eisen, T, Sternberg, CN, Robert, C, et al. Targeted therapies for renal cell carcinoma: review of adverse event management strategies. J Natl Cancer Inst 104 (2012), 93–113.
20. 20 Motzer, RJ, Escudier, B, Oudard, S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116 (2010), 4256–4265.
21. 21 McKay, RR, Kroeger, N, Xie, W, et al. Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. Eur Urol 65 (2014), 577–584.
22. 22 Choueiri, TK, Pal, SK, McDermott, DF, et al. A phase I study of cabozantinib (XL184) in patients with renal cell cancer. Ann Oncol 25 (2014), 1603–1608.
23. 23 Graham, TJ, Box, G, Tunariu, N, et al. Preclinical evaluation of imaging biomarkers for prostate cancer bone metastasis and response to cabozantinib. J Natl Cancer Inst, 106, 2014, dju033.
24. 24 Ciamporcero, E, Miles, KM, Adelaiye, R, et al. Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models. Mol Cancer Ther 14 (2015), 101–110.
25. 25 Motzer, RJ, Hutson, TE, Glen, H, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol 16 (2015), 1473–1482.
26. 26 Motzer, RJ, Hutson, TE, Tomczak, P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2007), 115–124.
27. 27 Escudier, B, Eisen, T, Stadler, WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27 (2009), 3312–3318.
28. 28 Sternberg, CN, Davis, ID, Mardiak, J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28 (2010), 1061–1068.
29. 29 Rini, BI, Escudier, B, Tomczak, P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378 (2011), 1931–1939.
30. 30 Motzer, RJ, Escudier, B, Oudard, S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372 (2008), 449–456.